Picture loading failed.

Anti-TPBG therapeutic antibody (Pre-made Naptumomab biosimilar,Fab Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-363-1mg 1mg 3090
GMP-Bios-ab-363-10mg 10mg 21890
GMP-Bios-ab-363-100mg 100mg 148000
GMP-Bios-ab-363-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TPBG therapeutic antibody (Pre-made Naptumomab biosimilar,Fab Fusion)
INN Name Naptumomab
TargetTPBG
FormatFab Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesActive Biotech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedNon-small cell lung cancer;Pancreatic cancer;Renal cancer
Development Techna